Nymox Pharmaceutical Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NYMXF research report →
Companynymox.com
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure.
- CEO
- Paul Averback
- IPO
- 1997
- Employees
- 16
- HQ
- Nassau, BS
Price Chart
Valuation
- Market Cap
- $9.13M
- P/E
- -2.01
- P/S
- 0.00
- P/B
- -1.34
- EV/EBITDA
- -2.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 90.31%
- ROIC
- 63.22%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,492,000 · 49.21%
- EPS
- $-0.05 · 50.26%
- Op Income
- $-4,283,000
- FCF YoY
- 35.94%
Performance & Tape
- 52W High
- $0.15
- 52W Low
- $0.03
- 50D MA
- $0.06
- 200D MA
- $0.06
- Beta
- 8.90
- Avg Volume
- 12.28K
Get TickerSpark's AI analysis on NYMXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NYMXF Coverage
We haven't published any research on NYMXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NYMXF Report →